UNIVERSITY OF BIRMINGHAM

University of Birmingham
Research at Birmingham

Renal dysfunction and diastolic impairment amongst British ethnic minorities with hypertension: The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES)

Shantsila, Alena; Shantsila, Eduard; Gill, Paramjit; Lip, Gregory

Document Version
Peer reviewed version

Link to publication on Research at Birmingham portal

1   **Renal dysfunction and diastolic impairment amongst British ethnic**

2   **minorities with hypertension:**

3   **The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES)**

4   *Running title:* Diastolic dysfunction in ethnic groups

5

6   Alena Shantsila[1], Eduard Shantsila[1], Paramjit S Gill[2]* Gregory Y.H. Lip[1]*

7

8   [1]University of Birmingham, Institute of Cardiovascular Sciences, City Hospital, Birmingham,

9   [2]Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK.

10

11

12

13

14 [*joint senior authors]

15 **Corresponding author:** Professor Gregory YH Lip, University of Birmingham, Institute of

16 Cardiovascular Sciences, City Hospital, Birmingham, Tel: +44 121 507 5080; Fax +121 507

17 5907; g.y.h.lip@bham.ac.uk

18

19

20

21

22

23

25

1   **Abstract**

2   Renal dysfunction is frequently associated with LV hypertrophy and diastolic dysfunction in

3   hypertensive patients. Limited data exist on renal dysfunction and diastolic impairment

4   amongst British ethnic minorities with hypertension. We studied associations between renal

5   impairment and diastolic dysfunction in hypertensive subjects of African-Caribbean and

6   South Asian origin. 510 hypertensive subjects with ejection fraction ≥55%, no history of

7   ischemic heart disease/valve pathology were included from the original population of the

8   Ethnic - Echocardiographic Heart of England Screening Study (E-ECHOES). Diastolic

9   function and cardiac remodeling were measured by echocardiography.

10 Left ventricular (LV) hypertrophy was common and present in 62% of patients with normal

11 estimated glomerular filtration rate (eGFR, >90 ml/min/$1.73m^2$), 73% in those with eGFR

12 60-89 and 87% with eGFR <60. On both univariate and multivariable linear regression,

13 reduced eGFR was associated with higher LV mass index (LVMI, p=0.01 and p=0.039,

14 respectively). On multivariable analyses, increased LVMI (but not eGFR) was an

15 independent predictor of echocardiographic parameters of diastolic dysfunction.   Higher

16 LVMI was an independent predictor of all cause or cardiovascular death on multivariable

17 analyses (both p=0.002), but not eGFR.

18 LV hypertrophy is common in minority ethnic groups with hypertension, especially in

19 presence of renal dysfunction. Increased LVMI rather than renal impairment per se is a major

20 determinant of diastolic dysfunction and increased risk of cardiovascular or all cause death

21 amongst hypertensive patients without end-stage renal failure.

22

1 **Introduction**

2

3 Hypertension is a major cause of diastolic dysfunction and heart failure with preserved

4 ejection fraction, with a significant contribution to cardiovascular and overall mortality.(1)

5 Hypertension also frequently leads to renal dysfunction, which increases the risk of

6 cardiovascular complications and death.(2, 3) However, renal dysfunction is frequently

7 associated with LV hypertrophy and diastolic impairment.(4, 5), although studies assessing

8 role of renal failure in diastolic dysfunction in hypertension have been mostly conducted on

9 subjects of White origin with advanced or end-stage renal failure. Limited data exist on renal

10 dysfunction and diastolic impairment amongst minority ethnic groups with hypertension.

11

12 The Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES) study was a

13 cross-sectional population survey of subjects of South Asian and African-Caribbean origin

14 aged ≥45 years. The study participants were recruited from 20 primary care centres in

15 Birmingham, United Kingdom between September 2006 to August 2009 and had

16 comprehensive clinical assessment and echocardiography performed.(6) In this analysis, we

17 aimed to study the associations between renal impairment and diastolic dysfunction in

18 hypertensive subjects of African-Caribbean and South Asian origin.

19

Methods

We included participants of the E-ECHOES study who had history of hypertension with normal left ventricular (LV) systolic function (i.e., LV ejection fraction ≥55% by echocardiography), no history of ischemic heart disease (i.e., no angina, previous coronary revascularization or myocardial infarction or use of nitrates) and measured plasma creatinine. Other exclusion criteria were abnormalities of cardiac valves (i.e., stenosis or more than mild regurgitation of any valve or previous valve surgery), history of peripheral artery disease, cancer, chronic obstructive pulmonary disease, atrial fibrillation, current treatment with digoxin, warfarin, ADP (adenosine diphosphate receptor) antagonists or antiarrhythmic agents (except beta-blockers or calcium antagonists). The E-ECHOES database had 5353 entries including 2675 patients with hypertension. From this population, 510 patients consented to have serum creatinine measured at the time of the recruitment.

The E-ECHOES study was approved by Walsall Local Research Ethics Committee (05/Q2708/45) with all participants provided written informed consent for data collection and analysis. Cases of deaths and their causes were provided by the Office of National Statistics.

Echocardiography

All study participants underwent detailed echocardiographic analysis with images reviewed by a consultant cardiologist with expertise in echocardiography. Echocardiography was done in primary care settings using a portable VIVID i machine (GE Healthcare, Chalfont St Giles, UK). LV ejection fraction, dimensions of cardiac chambers, LV mass index and parameters of diastolic function (mitral valve E/A ratio; E wave deceleration time; and isovolumic relaxation time (IVRT), tissue Doppler imaging of lateral and septal mitral valve annulus to

1   quantify E/e' ratio) were also measured in accordance with current recommendations.(7)

2   Diastolic dysfunction was determined based on E/A ratio and average septal-lateral E/e' as

3   main criteria and additional criteria of abnormal deceleration time (<130 msec or >230

4   msec), reduced e' velocity (e' septal <8 cm/sec or e' lateral <10 cm/sec) and increased LA

5   diameter (>4.0 cm in men and >3.8 cm in women). Diastolic dysfunction was defined as (i)

6   E/A <1 (in patients older 60 years only in presence of ≥1 additional factor); (ii) E/A ≥1, E/e'

7   8-13 and ≥1 additional factor, or (iii) E/A ≥1 and E/e' ≥13. Coding was done by an

8   independent physician who was not involved in any analyses or writing of the manuscript

9   (MD, see acknowledgments).

10

11   Increased LV filling pressure was defined based on average septal/lateral E/e'

12   ≥13).(8) In order to assess the separate components of diastolic function, average

13   septal/lateral e' velocity (as a measure of active relaxation) and the ratio of E/e' ratio: LV

14   diastolic volume index (as an index of passive diastolic stiffness). LV hypertrophy was

15   defined as LV mass index >95 g/m2 in women and 115 g/m2 in men.(7) Concentric

16   hypertrophy was defined as the relative wall thickness was ≤0.42; eccentric hypertrophy as

17   the relative wall thickness >0.42 (both in presence of increased LV mass index). Concentric

18   remodelling was defined as a normal LV mass index with relative wall thickness >0.42.(7)

19   Intra- and interobserver variability of measurements of standard parameters of diastolic

20   function in the department was <10%.(9)

21

22   *Statistical analysis*

23   Normal data are presented as mean ± standard deviation and compared using independent

24   sample T-test. Forward stepwise regression was used to establish predictors of parameters of

25   diastolic dysfunction with the following predictor variables tested: age, gender, history of

diabetes and smoking, systolic and diastolic blood pressure, heart rate, body mass index, waist circumference, use of angiotensin enzyme inhibitors or angiotensin receptor antagonists, aldosterone antagonist, alpha-blocker, calcium channel blocker, diuretic, aspirin, statin, LV mass index (the last parameter was not used in analyses of predictors of LV mass index itself). The variables for the regression analysis have been chosen based on previous literature on diastolic dysfunction and its predictors. Linear regression was used to establish predictors of continues variable and logistic regression was used to find predictors of diastolic dysfunction and increased LV filling pressure). Cox regression analysis was used to establish predictors of all-cause mortality in the study population. For logistic regression and Cox regression analyses, patients were categorised based on eGFR level ($\geq$90 ml/min/1.73m^2, 60-89 ml/min/1.73m^2, and < 60 ml/min/1.73m^2). IBM SPSS Statistics 21 (IBM Inc, USA) was used for statistical analyses. P-values of <0.05 were considered as statistically significant.

Results

A total of 510 patients (239 of South Asian origin and 271 of African Caribbean origin) met the analysis criteria and had information on eGFR. eGFR was normal ($\geq$90 ml/min/1.73m^2) in 352 (69%) subjects (*Group 1*), 128 (25%) had eGFR 60-89 ml/min/1.73m^2 (*Group* 2), 30 (6%) had eGFR <60 ml/min/1.73m^2 (*Group 3*, included 25 patients with eGFR 30-59 ml/min/1.73m^2, 2 with eGFR 15-29 ml/min/1.73m^2 and 3 with eGFR <15 ml/min/1.73m^2).

Patients with reduced eGFR were older than those with normal eGFR (p<0.001), had lower diastolic blood pressure (p<0.001), were more often prescribed aspirin (p=0.007) and statins (p=0.001) (Table 1). Calcium channel blockers were more often used in the Group 2 than in Group 1 (p=0.039) and Group 3 (p=0.016). Diuretics were more often used in Group 3 than in Group 1 (p=0.024). Otherwise demographic and clinical parameters were similar in the study groups.

Cardiac remodelling and diastolic dysfunction

LV hypertrophy was common and present in 62% of patients in Group 1, 73% in Group 2 and 87% in Group 3 (Figure 1). Patients with reduced eGFR were more likely to have abnormal LV geometry (i.e., LV hypertrophy or concentric LV remodelling) compared to those with normal eGFR (p=0.0498 for the Group 2 and p=0.046 for the Group 3). None of the Group 3 patients had normal LV geometry. Concentric LV hypertrophy was the predominant type of LV geometry in patients with reduced eGFR (50% of Group 2 and 59% of Group 3) (Table 1). Diastolic dysfunction was present in 67% of Group 1 and it was more common in Group 3 (87%, p=0.023) with similar trend for Group 2 (75%, p=0.075) (Table

1). Increased LV filing pressure was seen in 6% of Group 1 compared to 20% of Group 3

(p=0.003) with similar trend Group 2 (10%, p=0.075) (Table 1).

Both on univariate and multivariable linear regression, reduced eGFR was associated with

higher LV mass index (p=0.01 and p=0.039, respectively). On univariate regression analysis

reduced eGFR was associated with presence diastolic dysfunction (p=0.029), increased LV

filling pressure (p=0.011), increased LA diameter index (p=0.002) and e' velocity (p=0.001)

(Tables 2 and 3). On multivariable analyses including adjustment for LV mass index, eGFR

was not independently predictive of these parameters, nor E/e' ratio : LV diastolic volume

index (p>0.05 for all) (Tables 2 and 3). In contrast, increased LV mass index was

independently associated with all echocardiographic parameters of diastolic dysfunction

above.

Mortality

Twenty nine deaths (6%) including 12 cardiovascular deaths occurred during follow up of

71 ± 10 months. On univariate Cox regression eGFR <60 ml/min/1.73m^2 was associated with

increased risk of all cause death (hazard ratio (HR) 3.24, 95% confidence interval 1.08-9.78,

p=0.037) (Table 4). A nonsignificant trend was seen for the risk of cardiovascular death (HR

4.09, 95%CI 0.83-20.3, p=0.085). On multivariable Cox analyses, higher LV mass index was

independently associated with increased risk of both all cause (HR 1.09, 95%CI 1.03-1.14,

p=0.002) and cardiovascular death (HR 1.11, 95%CI 1.04-1.19, p=0.002) (Table 4), but

eGFR was non-predictive.

Discussion

The study shows for the first time a significant independent association between relatively mild renal impairment and unfavorable LV remodeling in minority ethnic groups with hypertension without end-stage renal failure. In this population, reduced eGFR had an independent liner relationship with increased LV mass index after accounting for known contributors to development of LV hypertrophy.

Association of renal dysfunction with LV hypertrophy is well established in predominantly White populations.(10) Reported frequency of LV hypertrophy varies depending on severity of renal dysfunction, being in the range of 16-31% in patients with chronic kidney disease stage 3 or better, 60–75% of predialysis subjects and over 90% in dialysis patients.(4) However, the present study shows a higher than expected occurrence of LV hypertrophy amongst ethnic minority groups in the UK. Indeed, LV hypertrophy was evident in 62% of patients with normal eGFR and reached 87% in those with eGFR <60 ml/min/1.73m^2. Establishment of the precise causes for the frequent occurrence of LV hypertrophy in this population would require further research but may be due to suboptimal compliance with treatments, ethnicity related factors or relatively elderly study population.

We show that LV hypertrophy is the pivotal factor of developing of diastolic dysfunction and increased LV filling pressure. Indeed, non-end-stage renal dysfunction lost its predictive value for these parameters after adjustment for LV mass index. In contrast, elevated LV mass index was independently associated with presence of both diastolic dysfunction and increased LV filling pressure. Indeed, left atrial diameter index (a marker of chronic diastolic dysfunction), isovolumic relaxation time (a measure of overall relaxation), e' velocity (a

measure of active relaxation) and E/e' ratio : LV diastolic volume index (an index of passive diastolic stiffness) showed no independent association with eGFR in an analysis adjusted for LV mass index. Again, high LV mass index was an independent predictor of all these characteristics of diastolic dysfunction, thus confirming the key role of LV hypertrophy in diastolic dysfunction in hypertension.

Previous studies indicate that several types of myocardial changes contribute to diastolic dysfunction in hypertension including LV hypertrophy, delayed relaxation and increased stiffness of cardiomyocytes and LV fibrosis.(11-13) In the Framingham study in the population free from any cardiovascular disease and aged 40 years or older, the LV hypertrophy was present in 16% of man and 21% of women. (14) This study of the ethic groups in the UK shows considerably higher prevalence of LV hypertrophy, which could be due to age effect. To account the analyses for the age effect we included age in all multivariate models in this study. LV hypertrophy is primarily driven by cardiac remodeling in response to high blood pressure, but the magnitude of LV hypertrophy is also affected by extracardiac target organ damage, such as abnormal arterial stiffness, impaired cardiac-vascular coupling and renal dysfunction.(15) Chronic kidney disease is a frequent complication of hypertension and it does contribute to poor outcome in such patients.

Myocardial hypertrophy and associated cardiac remodeling parallel increase in extracellular matrix production leading to fibrosis.(16) Cardiac fibrosis is also promoted by activation of renin-angiotensin-aldosterone system, typical of hypertension and renal dysfunciton.(17) Pathological cardiac fibrosis increases cardiac stiffness and impairs LV contractility, leading to both systolic and diastolic dysfunction and congestive heart failure.(18) However increased LV hypertrophy rather than cardiac fibrosis appear to be the principal factor

leading to diastolic dysfunction in patients with preserved LV contractility and without end-stage renal failure, as seen in our analysis.

The clinical significance of LV hypertrophy rather than eGFR reduction per se in hypertensive patients without end-stage failure is further supported by increased LV mass index (but not eGFR) being independently predictive of mortality in this study. This observation accords well with previous data from White populations, including those with end-stage renal disease.(19) In advanced renal failure, almost half of deaths have been related to cardiovascular events but risk of such events was much lower in predialysis cohorts.(2, 3, 20) These data have clinical implication as 10% decrease in LV mass has been translated into a 28% reduction in cardiovascular mortality in patients receiving hemodialysis, highlighting the role of LV mass index as a useful marker of effectiveness of blood pressure control.(21)

Limitations

The study population mostly included patients with normal or mildly-to-moderately impaired renal function and the results may not be applicable to patients with end-stage renal failure. Kidney function assessment was based only on eGFR estimation. Lack of comparison group of White origin prevents generalization of the findings to all ethnic groups. Associations between renal function and systolic dysfunction should ideally be analyzed in prospective cohort studies but this was beyond the scope of the current analysis.

Conclusions

LV hypertrophy is common in ethnic minority groups with hypertension, especially so in presence of renal dysfunction. Increased LVMI rather than renal impairment per se is a major

1   determinant of diastolic dysfunction and increased risk of cardiovascular or all cause death

2   amongst hypertensive patients without end-stage renal failure.

3

22

REFERENCES

1.   Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-77.

2.   Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. Journal of cardiac failure. 2007;13(6):422-30.

3.   Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. Journal of the American Society of Nephrology : JASN. 2006;17(7):2034-47.

4.   Di Lullo L, Floccari F, Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clinical practice. 2011;118(3):c257-61.

5.   Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clinical journal of the American Society of Nephrology : CJASN. 2009;4 Suppl 1:S79-91.

6.   Gill PS, Calvert M, Davis R, Davies MK, Freemantle N, Lip GY. Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). PloS one. 2011;6(11):e26710.

7.   Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2006;7(2):79-108.

1   8.   Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al.

2   Recommendations for the evaluation of left ventricular diastolic function by

3   echocardiography. European journal of echocardiography : the journal of the Working Group

4   on Echocardiography of the European Society of Cardiology. 2009;10(2):165-93.

5   9.   Butt M, Khair OA, Dwivedi G, Shantsila A, Shantsila E, Lip GY. Myocardial

6   perfusion by myocardial contrast echocardiography and endothelial dysfunction in

7   obstructive sleep apnea. Hypertension. 2011;58(3):417-24.

8   10.   London GM. Left ventricular alterations and end-stage renal disease. Nephrology,

9   dialysis, transplantation : official publication of the European Dialysis and Transplant

10   Association - European Renal Association. 2002;17 Suppl 1:29-36.

11   11.   Ritz E, Wanner C. The challenge of sudden death in dialysis patients. Clinical journal

12   of the American Society of Nephrology : CJASN. 2008;3(3):920-9.

13   12.   Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia--

14   beyond coronary heart disease. Semin Dial. 2008;21(4):308-18.

15   13.   Ritz E. Left ventricular hypertrophy in renal disease: beyond preload and afterload.

16   Kidney international. 2009;75(8):771-3.

17   14.   Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications

18   of echocardiographically determined left ventricular mass in the Framingham Heart Study. N

19   Engl J Med. 1990;322(22):1561-6.

20   15.   Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular

21   hypertrophy on survival in end-stage renal disease. Kidney international. 1989;36(2):286-90.

22   16.   Dorn GW, 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in

23   ventricular remodelling. Cardiovascular research. 2009;81(3):465-73.

1   17.   Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R. Role of aldosterone in left

2   ventricular hypertrophy among African-American patients with end-stage renal disease on

3   hemodialysis. Am J Nephrol. 2007;27(2):159-63.

4   18.   Zoccali C, Benedetto FA, Tripepi G, Mallamaci F. Cardiac consequences of

5   hypertension in hemodialysis patients. Semin Dial. 2004;17(4):299-303.

6   19.   Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al.

7   Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left

8   ventricular hypertrophy progression. Kidney international. 2004;65(4):1492-8.

9   20.   Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart

10   failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney

11   international. 1995;47(3):884-90.

12   21.   London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al.

13   Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis:

14   follow-up of an interventional study. Journal of the American Society of Nephrology : JASN.

15   2001;12(12):2759-67.

16

Summary Table.

What is known about topic

- Hypertension is a major cause of diastolic dysfunction and heart failure with preserved ejection fraction, with a significant contribution to cardiovascular and overall mortality

- Hypertension also frequently leads to renal dysfunction, which increases the risk of cardiovascular complications and death

- Renal dysfunction is frequently associated with left ventricular hypertrophy and diastolic dysfunction in hypertensive patients

What this study adds

- Increased left ventricular mass index rather than non-end stage renal impairment per se is a major determinant of diastolic dysfunction in ethnic minority groups with hypertension.

- Increased left ventricular mass index is associated with high risk of cardiovascular and all cause death amongst hypertensive patients without end-stage renal failure.

1   Figure 1. The prevalence of left ventricular hypertrophy and diastolic dysfunction

2   across the categories of renal function.

3
4   DD, diastolic dysfunction; LVH, left ventricle hypertrophy; Group 1, eGFR ≥90

5   ml/min/1.73m^2; Group 2 eGFR 60-89 ml/min/1.73m^2 ; Group 3 eGFR <60

6   ml/min/1.73m^2.